Articles related to DYSLIPIDEMIA

In a secondary analysis of 371,038 U.S. adults, individuals reporting several cardiovascular disease (CVD) risk factors or established CVD reported less frequent whole-fruit consumption. The cross-sectional survey identified associations only and did not establish whether dietary behaviors preceded disease.

Analysis of NHANES data suggests that adoption of the 2026 ACC/AHA dyslipidemia guidelines could make approximately 25 million additional US adults eligible to consider statin therapy, primarily through incorporation of PREVENT risk equations and expanded emphasis on long-term cardiovascular risk.

Atorvastatin reduced major cardiovascular events among adults aged 70 years and older without known cardiovascular disease, diabetes, or dementia, but the benefit did not translate into a statistically significant improvement in disability-free survival over nearly six years of follow-up.

Double-filtration plasmapheresis reduced circulating concentrations of several PFAS in small patient samples, while microplastic changes varied by polymer. The exploratory findings do not support apheresis for environmental pollutant removal.

A systematic review and meta-analysis found that inclisiran significantly reduced LDL cholesterol compared with placebo across diverse hyperlipidemia populations. Long-term cardiovascular outcome data remain limited despite consistent lipid-lowering efficacy and favorable safety findings.

Discontinuing statins in adults 75 years and older without prior cardiovascular disease did not increase mortality or major cardiovascular events over three years in a randomized trial. LDL cholesterol rose substantially after discontinuation, and longer-term effects remain uncertain.